NATERA INC (NTRA)

US6323071042 - Common Stock

161.88  +3.79 (+2.4%)

After market: 161.88 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to NTRA. NTRA was compared to 565 industry peers in the Biotechnology industry. The financial health of NTRA is average, but there are quite some concerns on its profitability. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

NTRA had negative earnings in the past year.
NTRA had a positive operating cash flow in the past year.
NTRA had negative earnings in each of the past 5 years.
NTRA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NTRA has a Return On Assets of -13.49%. This is amongst the best in the industry. NTRA outperforms 85.13% of its industry peers.
With an excellent Return On Equity value of -24.44%, NTRA belongs to the best of the industry, outperforming 82.12% of the companies in the same industry.
Industry RankSector Rank
ROA -13.49%
ROE -24.44%
ROIC N/A
ROA(3y)-35.86%
ROA(5y)-30.73%
ROE(3y)-68.88%
ROE(5y)-59.73%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NTRA's Gross Margin of 57.66% is fine compared to the rest of the industry. NTRA outperforms 78.58% of its industry peers.
NTRA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NTRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y5.07%

More info and screens

5

2. Health

2.1 Basic Checks

NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NTRA has been increased compared to 5 years ago.
Compared to 1 year ago, NTRA has an improved debt to assets ratio.

2.2 Solvency

NTRA has an Altman-Z score of 17.02. This indicates that NTRA is financially healthy and has little risk of bankruptcy at the moment.
NTRA's Altman-Z score of 17.02 is amongst the best of the industry. NTRA outperforms 91.15% of its industry peers.
NTRA has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
NTRA has a worse Debt to Equity ratio (0.42) than 72.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Altman-Z 17.02
ROIC/WACCN/A
WACC10.85%

2.3 Liquidity

NTRA has a Current Ratio of 4.39. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NTRA (4.39) is comparable to the rest of the industry.
NTRA has a Quick Ratio of 4.23. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
NTRA's Quick ratio of 4.23 is in line compared to the rest of the industry. NTRA outperforms 50.44% of its industry peers.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.23

More info and screens

6

3. Growth

3.1 Past

NTRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.06%, which is quite impressive.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 54.93%.
Measured over the past years, NTRA shows a very strong growth in Revenue. The Revenue has been growing by 33.25% on average per year.
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.63%
Revenue 1Y (TTM)54.93%
Revenue growth 3Y40.42%
Revenue growth 5Y33.25%
Sales Q2Q%63.9%

3.2 Future

Based on estimates for the next years, NTRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.47% on average per year.
The Revenue is expected to grow by 19.51% on average over the next years. This is quite good.
EPS Next Y56.6%
EPS Next 2Y29.19%
EPS Next 3Y26.27%
EPS Next 5Y15.47%
Revenue Next Year54.36%
Revenue Next 2Y30.9%
Revenue Next 3Y26.36%
Revenue Next 5Y19.51%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NTRA's earnings are expected to grow with 26.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.19%
EPS Next 3Y26.27%

More info and screens

0

5. Dividend

5.1 Amount

NTRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NATERA INC

NASDAQ:NTRA (12/20/2024, 8:00:01 PM)

After market: 161.88 0 (0%)

161.88

+3.79 (+2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners97.57%
Inst Owner Change0.68%
Ins Owners3.66%
Ins Owner Change2.76%
Market Cap21.37B
Analysts85.6
Price Target177.54 (9.67%)
Short Float %3.18%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.48%
Min EPS beat(2)55.66%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)37.22%
Min EPS beat(4)13.75%
Max EPS beat(4)57.31%
EPS beat(8)7
Avg EPS beat(8)20.69%
EPS beat(12)10
Avg EPS beat(12)14.61%
EPS beat(16)11
Avg EPS beat(16)7.34%
Revenue beat(2)2
Avg Revenue beat(2)18.71%
Min Revenue beat(2)18.14%
Max Revenue beat(2)19.28%
Revenue beat(4)4
Avg Revenue beat(4)14.55%
Min Revenue beat(4)6.8%
Max Revenue beat(4)19.28%
Revenue beat(8)7
Avg Revenue beat(8)8.56%
Revenue beat(12)10
Avg Revenue beat(12)6.32%
Revenue beat(16)14
Avg Revenue beat(16)7.47%
PT rev (1m)1.56%
PT rev (3m)34.75%
EPS NQ rev (1m)0.56%
EPS NQ rev (3m)16.16%
EPS NY rev (1m)18.35%
EPS NY rev (3m)18.02%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)10.07%
Revenue NY rev (1m)7.49%
Revenue NY rev (3m)7.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.95
P/FCF N/A
P/OCF 866.92
P/B 24.33
P/tB 24.33
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)0.19
OCFY0.12%
SpS11.6
BVpS6.65
TBVpS6.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.49%
ROE -24.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.66%
FCFM N/A
ROA(3y)-35.86%
ROA(5y)-30.73%
ROE(3y)-68.88%
ROE(5y)-59.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y5.07%
F-Score7
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 227.12%
Cap/Sales 4.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.23
Altman-Z 17.02
F-Score7
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)296.37%
Cap/Depr(5y)236.21%
Cap/Sales(3y)5.79%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.63%
EPS Next Y56.6%
EPS Next 2Y29.19%
EPS Next 3Y26.27%
EPS Next 5Y15.47%
Revenue 1Y (TTM)54.93%
Revenue growth 3Y40.42%
Revenue growth 5Y33.25%
Sales Q2Q%63.9%
Revenue Next Year54.36%
Revenue Next 2Y30.9%
Revenue Next 3Y26.36%
Revenue Next 5Y19.51%
EBIT growth 1Y51.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.62%
EBIT Next 3Y29.08%
EBIT Next 5Y15.38%
FCF growth 1Y91.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.49%
OCF growth 3YN/A
OCF growth 5YN/A